

Grünenthal GmbH

[View the current Grünenthal GmbH Page on BioPortfolio.com](http://www.bioportfolio.com/biorporate/23731-Gr%FCnenthal+GmbH.html)

(<http://www.bioportfolio.com/biorporate/23731-Gr%FCnenthal+GmbH.html>)

Contact Details:

Aachen

D-52099
Germany

Tel: 49 241 569 - 1522

Fax:

Email: info@grunenthal.com

Nil

Recent Publications by Grünenthal GmbH:



- [Tapentadol hydrochloride: A next-generation, centrally acting analgesic with two mechanisms of action in a single molecule.](#)
*Tapentadol exerts its analgesic effects through micro opioid receptor...*17th October, 2009
Grunenthal- Drugs Today (Barc). 2009 Jul;45(7):483-96. ([DOI Direct Link](#))
- [Comparative effects of chlormadinone acetate and its 3alpha- and 3beta-hydroxy metabolites on progesterone, androgen and glucocorticoid receptors.](#)
*AIM/METHODS: In vitro binding tests to human receptors and in vivo...*11th July, 2009
Preclinical Development, Grunenthal GmbH, Aachen, Germany.- Pharmacology. 2009;84(2):74-81.
Epub 2009 Jul 3. ([DOI Direct Link](#))
- [Investigations into the drug-drug interaction potential of tapentadol in human liver microsomes and fresh human hepatocytes.](#)
*The new analgesic tapentadol was evaluated for induction and inhibition of...*13th May, 2009
Grunenthal GmbH- Drug Metab Lett. 2008 Jan;2(1):67-75.
- [A randomized, double-blind, phase III study comparing multiple doses of tapentadol IR, oxycodone IR, and placebo for postoperative \(bunionectomy\) pain *](#)
*ABSTRACT Objective: This study evaluated tapentadol immediate release (IR)...*11th February, 2009
aPremier Research, Austin, TX, USA, bJohnson & Johnson Pharmaceutical- Curr Med Res Opin. 2009 Feb 10. ([DOI Direct Link](#))
- [Cost-effectiveness analysis of a lidocaine 5% medicated plaster compared with gabapentin and pregabalin for treating postherpetic neuralgia: a german perspective.](#)

- OBJECTIVE: This study set out to assess the cost effectiveness of using a...*7th January, 2009
Grunenthal- Clin Drug Investig. 2008;28(9):583-601.
- [Single dose analgesic efficacy of tapentadol in postsurgical dental pain: the results of a randomized, double-blind, placebo-controlled study.](#)
*BACKGROUND: Tapentadol is a novel, centrally acting analgesic with two...*31st December, 2008
Grunenthal GmbH, Zieglerstr. 6 52078, Aachen, Germany.- Anesth Analg. 2008 Dec;107(6):2048-55. ([DOI Direct Link](#))
 - [Differential effects of morphine on the affective and the sensory component of carrageenan-induced nociception in the rat.](#)
*Pain is generally considered to have a sensory and an affective component...*8th July, 2008
Grunenthal GmbH, Preclinical Research and Development, Department of- Pain. 2008 Jun;136(3):373-9. Epub 2007 Sep 6. ([DOI Direct Link](#))
 - [Effect of 2-methyl-6-\(phenylethynyl\) pyridine on intravenous self-administration of ketamine and heroin in the rat.](#)
*The mGluR5 antagonist 2-methyl-6-(phenylethynyl) pyridine (MPEP) may be...*25th January, 2008
Grunenthal GmbH, Preclinical Research and Development, Department of- Behav Pharmacol. 2007 Dec;18(8):717-24. ([DOI Direct Link](#))
 - [Switching hormonal contraceptives to a chlormadinone acetate-containing oral contraceptive. The Contraceptive Switch Study.](#)
*PURPOSE: This prospective observational noninterventional study aimed at...*4th January, 2008
Grunenthal GmbH, Medical Department, 52099 Aachen, Germany.- Contraception. 2007 Aug;76(2):84-90. Epub 2007 Jun 11. ([DOI Direct Link](#))
 - [Absorption, metabolism, and excretion of 14C-labeled tapentadol HCl in healthy male subjects.](#)
*Tapentadol is a novel, centrally acting oral analgesic with a dual mode of...*28th December, 2007
Grunenthal GmbH, Preclinical Research and Development/Department of- Eur J Drug Metab Pharmacokinet. 2007 Jul-Sep;32(3):163-9.
 - [\(-\)-\(1R,2R\)-3-\(3-dimethylamino-1-ethyl-2-methyl-propyl\)-phenol hydrochloride \(tapentadol HCl\): a novel mu-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties.](#)
*(-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol...*6th November, 2007
Department of Pharmacology, Grunenthal GmbH, Aachen, Germany.- J Pharmacol Exp Ther. 2007 Oct;323(1):265-76. Epub 2007 Jul 26. ([DOI Direct Link](#))
 - [Measuring reward with the conditioned place preference \(CPP\) paradigm: update of the last decade.](#)
*Conditioned place preference (CPP) continues to be one of the most popular...*1st November, 2007
Grunenthal GmbH, Preclinical Research and Development, Department of- Addict Biol. 2007 Sep;12(3-4):227-462. ([DOI Direct Link](#))
 - [Tramadol has a better potency ratio relative to morphine in neuropathic than in nociceptive pain models.](#)
*BACKGROUND AND OBJECTIVE: Treatment of neuropathic pain remains a...*19th June, 2007
Biomedical Research, Grunenthal GmbH, Aachen, Germany.- Drugs R D. 2007;8(1):51-7.
 - [Economic evaluation of tramadol/paracetamol combination tablets for osteoarthritis pain in the Netherlands.](#)
*OBJECTIVE: To compare the costs of treating osteoarthritis (OA) pain using...*30th May, 2007
Grunenthal GmbH, Aachen, Germany.- Clin Drug Investig. 2005;25(12):785-802.

Press Releases on Grünenthal GmbH:

Reportlinker Adds Power Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015	20th November, 2009	Reportlinker	NEW YORK, Nov. 20 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Power Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, NEW YORK, Nov. 20 /PRNewswire/ --
Reportlinker Adds Stethoscopes - A Worldwide Market Intelligence Report	20th November, 2009	Reportlinker	Reportlinker.com announces that a new market research report is available in its catalogue. Stethoscopes - A Worldwide Market Intelligence Report http://www
Quark Reports Progress of siRNA Clinical Programs; 300 Patients Dosed With Quark Pharmaceuticals's siRNA Drugs In Multiple Fully Enrolled Clinical Trials	19th November, 2009	Quark Pharmaceuticals, Inc.	-- Pfizer Inc., which licenses PF-4523655 from Quark, has completed enrollment in a Phase 2 study of PF-4523655 in patients with diabetic macular edema (DME). PF-4523655 is
MONITORING FORCE GmbH Requests Acknowledgment of Flibanserin as "Orphan Drug"	19th November, 2009	MONITORING FORCE GmbH	MUNSTER, Germany, November 19 /PRNewswire/ -- MONITORING FORCE GmbH announced that they have filed on November 16th, 2009 Flibanserin in the indication treatment-relevant levodopa-induced
Germany-Based caprotec bioanalytics Opens US Subsidiary in Burlington, Massachusetts; Appoints President	19th November, 2009	caprotec bioanalytics GmbH	BURLINGTON, Mass. and BERLIN, Nov. 19 /PRNewswire/ -- caprotec bioanalytics GmbH announced today the opening of its US-based subsidiary based in Burlington, MA. caprotec Inc. will be responsible for

- [Grüenthal to focus on pain-relief drugs](#)

Therapeutics Daily: Oct 16 2009 12:30PM Matching: gruenenthal gmbh

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

